Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals Nov 18, 2025
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens Nov 10, 2025
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference Oct 28, 2025
Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update Oct 27, 2025
Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection Sep 30, 2025
Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules Sep 3, 2025
